Results 11 to 20 of about 10,088 (191)
Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota.
Lung Chan, Yun-Ru Liu, Hsun-Hua Lee
exaly +4 more sources
Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
Rifaximin is an antibiotic characterized by polymorphism. It has various crystalline forms with different pharmacological characteristics. Rifaximin acts locally in the digestive tract, therefore it is important for the absorption to be minimal and for ...
S. K. Zyryanov, E. A. Baybulatova
doaj +2 more sources
High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome [PDF]
John JolleyDepartment of Medicine, University of California, San Francisco, CA, USABackground: To evaluate the efficacy of rifaximin for reduction of gastrointestinal symptoms in patients with irritable bowel syndrome (IBS).Methods: Medical records were ...
Jolley J
doaj +2 more sources
Beyond Prophylaxis: Antimicrobial Stewardship for Bacterial Infections in Cirrhosis. [PDF]
United European Gastroenterology Journal, Volume 14, Issue 9, November 2026.
Haedge F, Mücke MM, Lange CM, Bruns T.
europepmc +2 more sources
Rifaximin is FDA-approved for treatment of irritable bowel syndrome with diarrhea (IBS-D), but poor solubility may limit its efficacy against microbes in the mucus layer, e.g. Escherichia coli. Here we evaluate adding the mucolytic N-acetylcysteine (NAC)
Gabriela Leite +12 more
doaj +2 more sources
The Pros & Cons of Measuring Plasma Ammonia in the Management of Patients With Cirrhosis: An ISHEN Debate [PDF]
ABSTRACT Ammonia is a nitrogenous molecule which is primarily generated in the gastrointestinal tract. The neurotoxicity of ammonia plays a critical role in the liver's regulation of circulating ammonia levels. In liver disease, an increase in blood ammonia has been long implicated in the pathogenesis of hepatic encephalopathy (HE), a neurological ...
Ballester M, Bloom P, Rose C.
europepmc +2 more sources
The Use of Rifaximin in Patients With Cirrhosis [PDF]
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical
Caraceni, Paolo +46 more
core +8 more sources
Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy. [PDF]
Chemotherapy-induced intestinal mucositis is a frequent and dose-limiting toxicity that compromises cancer treatment outcomes and lacks effective targeted interventions.
Correale C +16 more
europepmc +2 more sources
Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort. [PDF]
Background/Aims Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting ...
Bajaj JS +14 more
europepmc +2 more sources
Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy ...
Jie Jian +9 more
doaj +1 more source

